Ondansetron Bristol Laboratories

Ondansetron, the active ingredient in Ondansetron Bristol Laboratories, is a 5-HT3 receptor antagonist presented as an oral dosage form for oral use. It is used to prevent and treat nausea and vomiting associated with chemotherapy, postoperative recovery, and radiotherapy in patients requiring antiemetic therapy.

GNH USA supplies Ondansetron Bristol Laboratories as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Ondansetron acts on serotonin 5‑HT3 receptors to control nausea and vomiting in several clinical settings.

- Chemotherapy‑induced nausea and vomiting: prevents and treats nausea and vomiting associated with cancer chemotherapy. - Postoperative nausea and vomiting: reduces the incidence of nausea and vomiting after surgical procedures. - Radiotherapy‑induced nausea and vomiting: helps control nausea and vomiting caused by radiation therapy.

Common Side Effects: - Headache: mild to moderate pain in the head. - Constipation: reduced bowel movements. - Diarrhoea: loose stools. - Dizziness: sensation of light‑headedness. - Fatigue: feeling unusually tired. - Abdominal pain: discomfort in the stomach area.

Serious or Rare Side Effects: - QT prolongation: abnormal heart rhythm that may lead to arrhythmia. - Severe allergic reaction: rash, swelling, or difficulty breathing. - Serotonin syndrome: agitation, fever, and muscle rigidity when combined with other serotonergic agents. - Cardiac arrhythmia: irregular heartbeats requiring medical attention. - Hepatic dysfunction: abnormal liver enzyme levels. - Hypotension: significant drop in blood pressure.

Before prescribing Ondansetron, consider patient-specific factors and monitor for potential risks.

- Cardiac history: assess for pre‑existing QT prolongation or arrhythmias. - Electrolyte balance: correct hypokalaemia or hypomagnesaemia to reduce cardiac risk. - Hepatic impairment: use caution and consider dose adjustment in liver disease. - Concomitant QT‑prolonging drugs: avoid or monitor closely when used together. - Renal impairment: adjust dose in severe kidney dysfunction. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Ondansetron may interact with several medications, requiring careful management.

Major Interactions (Avoid): - Apomorphine: concurrent use can cause severe hypotension and loss of consciousness. - Other QT‑prolonging agents (e.g., quinidine, erythromycin): increase risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - Carbamazepine: may reduce ondansetron plasma levels, decreasing efficacy. - Ritonavir: can increase ondansetron concentrations, raising side‑effect risk. - Aprepitant: may enhance antiemetic effect; monitor for additive QT prolongation.